Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular fingerprint of breast cancer drug resistance can predict response to treatment

25.09.2007
A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14) today (Monday 24 September).

Dr Iain Brown, from the University of Aberdeen, Aberdeen, Scotland, told the conference that he and his colleague, Dr Andrew Schofield, had identified two genes that could identify which cells would be resistant and which would respond to docetaxel.

Docetaxel is one of the most effective chemotherapy treatments in advanced breast cancer. It works by binding to cell components called microtubules, and stabilising them so that they do not disassemble. They then accumulate within the cell and bring about apoptosis, or cell death. “However, up to half of all patients treated with this drug will develop resistance, and hence the treatment will fail,” said Dr Brown.

The scientists decided to look for a specific genetic make-up in patients where docetaxel treatment had failed, in the hope that this might explain why they became resistant to the drug. They used micro-array analysis, a technique that allowed them to look at every known gene in our cells at once, to identify genes that were significantly associated with such resistance.

“By going back to the laboratory, using breast cancer cell lines, we can eliminate much of the variation in gene expression found in different patients, and thus remove a lot of ‘background noise’,” said Dr Brown. “We developed a unique model of docetaxel resistance in breast cancer from two different cell lines made resistant to the drug by exposing them to increasing concentrations of the drug. This model has also allowed us to test cells which are resistant to low levels of the drug and cells which are resistant to high levels.”

Drs Brown and Schofield now intend to carry the research further, by applying their findings to patient samples to see whether the gene set they have discovered has the ability to predict response to docetaxel in a patient who has undergone treatment with the drug. “At the moment we have only tested this in cell lines,” said Dr Brown, “but we do believe these results may be translated into the clinical setting and benefit the patient. In essence, we have taken a clinical problem back to the laboratory, and now we intend to take this back to the bedside.”

The scientists will start collecting tissue samples from patients within the next six months. “If we find the same results in patient samples, we would expect that a simple test for docetaxel resistance could be developed and in clinical use within the next five years,” said Dr. Brown. Such a test would mean that those who would not benefit from docetaxel chemotherapy could be spared its side effects, and also reduce costs for healthcare providers.

“We think that the changes we have found may represent common drug resistance mechanisms in breast cancer cells,” said Dr Brown. “We are currently looking at these findings in other cancer types, especially those which are also treated with docetaxel, to see if the results may have a potential in other areas. This is the first time that the genetic pathways involved in the evolution of acquired resistance to docetaxel have been identified in a docetaxel resistant cell line model.”

Mary Rice | alfa
Further information:
http://www.ecco-org.eu

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Climate change: In their old age, trees still accumulate large quantities of carbon

17.08.2017 | Earth Sciences

Modern genetic sequencing tools give clearer picture of how corals are related

17.08.2017 | Life Sciences

Superconductivity research reveals potential new state of matter

17.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>